(MedPage Today) — Children and adolescents with Tourette syndrome had a lower risk of relapses with investigational ecopipam, a phase III randomized withdrawal study showed.
Compared with placebo, ecopipam reduced relapse risk in 90 pediatric…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
